Biophytis Annual General Meeting We are pleased to invite you to the Biophytis Combined General Meeting which will be held following a second call in closed session on May 10 at 5:00 pm CET. The Combined General Meeting will be broadcast live (audio webcast) in two sessions: At 5pm CET in French, At 6pm CETin…
DetailsLive Stock Price
SEVERE ACUTE RESPIRATORY INFECTIONS: COVA CLINICAL PROGRAMME 1. Respiratory infections such as Covid-19 cause many hospital admissions and deaths According to the World Health Organisation (WHO), viral respiratory infections kill thousands of patients worldwide every year. In 2023, more than 230,000 patients died from COVID-19, out of a total of almost 7 million…
Details
Posters & Publications 2020 SARA program: the use of BIO101, a MAS receptor agonist, for the treatment of sarcopenia. Industry sponsored session, annual digital meeting of the Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD). Tourette et al. SARA program: Preliminary Findings & Implications from SARA-OBS Study and Its Impact on SARA-INT Study. Dioh et al.…
DetailsSEC Filings Filing Date Form Description September 30, 2024 6-K On September 30, 2024, Biophytis S.A. (the “Company”) issued its Interim Financial Report for the first half of fiscal year 2024. July 22, 2024 6-K On July 22, 2024, Biophytis S.A. issued a press release announcing the deployment of its partnership strategy in Asia. July…
DetailsRegulated Information In French: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2024 In French: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2024 In French: RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2024…
Details
Posters & Publications 2014 The SARCOB program: a french consortium for developing drug candidate and nutraceutical targeting sarcopenic obesity. Dioh et al. Poster presentation at the 5th International Conference on Frailty & Sarcopenia Research (ICFSR), March 12-14, 2014, Barcelona, Spain. Abstract published in The Journal of Frailty & Aging, 3(1), 72-73, Abstract P186.
Details
Posters & Publications 2015 BIO101, a drug candidate targeting sarcopenic obesity through MAS receptor activation. Raynal et al. Poster presentation at the 8th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 4-6, 2015, Paris, France. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 6(4), 429. Abstract 1-76.
Details
Posters & Publications 2016 BIO101, a drug candidate targeting Mas Receptor for the treatment of age-related muscle degeneration. From molecular target identification to clinical development. Dilda et al. Poster presentation at the 9th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 10-11, 2016, Berlin, Germany. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 7(5), 655. Abstract 4-01. A…
Details
Posters & Publications 2017 BIO103, a drug candidate for the treatment of muscle wasting disorders. Serova et al. Oral and poster presentations at the 10th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1067-1068. Abstract 8-09. SARA clinical program for evaluating safety and…
Details